SCHEDULE: Velan Capital Boosts Jasper Therapeutics Stake to 9.6%

Velan Capital and affiliated entities increased their beneficial ownership in Jasper Therapeutics, Inc. to 9.6% through a recent public offering, acquiring additional shares and warrants.

Summary

• Velan Capital Investment Management LP and its affiliates, including Velan Master Fund LP, Velan Horizon Fund LP, and Avego Healthcare Capital, L.P., collectively increased their beneficial ownership in Jasper Therapeutics, Inc. to 9.6% of the outstanding common stock.
• The increase in ownership resulted from participation in an underwritten public offering (the '2025 Offering') where Velan Master purchased 1,193,415 Shares and 1,193,415 Warrants, and Velan Horizon purchased 41,152 Shares and 41,152 Warrants.
• The shares and warrants in the 2025 Offering were acquired at a price of $2.43 per unit.
• The Warrants have an exercise price of $2.92 per Share, become exercisable on the six-month anniversary of their issuance, and expire four years thereafter.
• Certain reporting persons entered into a 90-day lock-up agreement with underwriters, restricting the sale or transfer of securities following the 2025 Offering.
• The aggregate beneficial ownership of the Velan Capital group, including Adam Morgan and Balaji Venkataraman, is 2,668,395 Shares, representing 9.6% of the 27,889,950 total Shares outstanding after the 2025 Offering.
• Vishal Kapoor, a director of Jasper Therapeutics and partner at Avego Management, beneficially owns 23,867 Shares (0.1%), including 19,492 shares from exercisable stock options.

Sentiment

Score: 7

Explanation: The increased stake by a prominent institutional investor group, Velan Capital, suggests a positive outlook and confidence in Jasper Therapeutics. While the offering itself implies dilution, the commitment from a sophisticated investor is generally viewed favorably.

Positives

• Increased institutional investment by Velan Capital and its affiliates signals confidence in Jasper Therapeutics' future prospects.
• The participation in the public offering demonstrates a continued commitment and potentially a long-term investment horizon from a significant investor group.

Negatives

• The public offering likely resulted in dilution for existing shareholders due to the issuance of new shares and warrants.
• A 90-day lock-up agreement restricts the immediate liquidity for the newly acquired shares and warrants for the reporting persons.

Risks

• The Warrants are not exercisable within 60 days of the filing date, meaning the potential for additional share issuance from warrant exercise is not immediate.
• The Warrants are subject to a 9.99% beneficial ownership blocker provision, which could limit the extent to which the reporting persons can increase their ownership through warrant exercise without further disclosures or adjustments.

Future Outlook

The warrants acquired in the 2025 Offering will become exercisable approximately six months from their issuance date and will remain exercisable for four years. Certain reporting persons are subject to a 90-day lock-up period following the underwriting agreement date, after which they will have greater flexibility in managing their holdings.

Industry Context

This filing reflects a significant institutional investment in a biotechnology company, a common occurrence in the sector where capital raises and strategic investments by specialized funds are crucial for funding research, development, and operational growth. The acquisition of warrants suggests a long-term bullish outlook on the company's potential.

Stakeholder Impact

• Shareholders: Experience dilution from the public offering but may benefit from increased institutional interest and confidence in the company.
• Company: Secures additional capital through the 2025 Offering, supporting operations and strategic initiatives.

Next Steps

• Expiration of the 90-day lock-up agreement for certain reporting persons, allowing for potential future transactions.
• Warrants acquired in the 2025 Offering will become exercisable on their six-month anniversary, potentially leading to further share acquisitions.

Key Dates

Recommendation

This filing primarily reports an update to beneficial ownership by an institutional investor group following a public offering. It does not contain information on the company's operational performance or financial results that would typically drive a 'buy' or 'sell' recommendation. However, the increased stake by a significant investor like Velan Capital could be interpreted as a positive signal, suggesting a 'hold' for existing investors and potential further analysis for new investors, rather than an immediate 'sell' or 'strong buy' based solely on this ownership update.

Keywords

Jasper Therapeutics, Velan Capital, Schedule 13D, Institutional Ownership, Public Offering, Warrants, Biotechnology, Healthcare Investment, Equity Stake, SEC Filing